Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma’s first-quarter 2026 results show a sharp strategic pivot after a key trial setback. Revenue from the Viatris collaboration grew to $17.7 million, driven by YUPELRI, while net loss narrowed to $4.9 million compared with $13.6 million a year earlier.
YUPELRI net sales recorded by Viatris reached $62.4 million, up 7%, implying $21.9 million for Theravance’s 35% share. Cash, cash equivalents and marketable securities totaled about $394.7 million with no long-term debt, boosted by TRELEGY and YUPELRI milestones.
After the ampreloxetine Phase 3 CYPRESS study failed its primary endpoint, the company is winding down the program, cutting about 50% of its 90 employees and implementing a restructuring expected to reduce operating expenses by roughly 60% versus 2025 and deliver about $70 million in annualized savings from the third quarter of 2026. A Board Strategic Review Committee is actively evaluating alternatives, including a possible sale of the company, while Theravance concentrates on its commercial YUPELRI franchise and remaining TRELEGY milestone upside.
Theravance Biopharma reported improved first-quarter 2026 results and detailed a major restructuring to become a cash-generative, YUPELRI-focused company. Revenue rose to $17.7 million from $15.4 million, and the GAAP net loss narrowed to $4.9 million from $13.6 million. Non-GAAP results turned to a $0.6 million profit versus an $8.6 million loss a year earlier, helped by YUPELRI net sales of $62.4 million recorded by Viatris, of which Theravance’s implied 35% share was $21.9 million.
The company plans an organizational restructuring that winds down R&D, cuts G&A about 50% and is expected to reduce operating expenses by roughly 60% versus 2025 actuals of $111.1 million. Management targets about $70 million of full run-rate cost savings and approximately $60–70 million of annualized cash flow starting in the third quarter of 2026, excluding any potential $100 million TRELEGY milestone. Around 50% of the workforce will be affected, with $5–7 million of one-time cash severance costs. A Board Strategic Review Committee continues to evaluate alternatives, including a potential sale of the company.
Theravance Biopharma, Inc. is asking shareholders to vote at its 2026 Annual General Meeting on June 12, 2026 in Dublin, Ireland. Shareholders will elect six directors to one‑year terms, ratify Ernst & Young LLP as independent auditor for 2026, and approve a non‑binding advisory vote on executive pay.
The board is being reduced from nine to six members and fully declassified, so all directors stand for annual election. The company highlights pay-for-performance features in 2025 executive compensation and details strong governance practices, independent board leadership, and active board committees overseeing strategy, risk, and capital allocation.
Theravance Biopharma CEO Rick E. Winningham received an equity grant of 75,000 Ordinary Shares at no cost. The award was recorded as a grant or other acquisition on Ordinary Shares.
Following this grant, he directly holds 1,651,094 Ordinary Shares and also reports indirect holdings of 23,400 shares as custodian and 92,567 shares held by a trust.
Sawaf Aziz reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that its SVP & Chief Financial Officer, Aziz Sawaf, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share, reflecting compensation rather than a market purchase.
Following this award, Mr. Sawaf directly holds 353,623 Ordinary Shares of Theravance Biopharma. This filing records a stock-based compensation grant to a senior executive, not an open-market buy or sell transaction.
Grimaud Brett A. reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. executive Brett A. Grimaud, SVP, General Counsel and Secretary, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings increased to 371,949 Ordinary Shares, according to the filing.
Farnum Rhonda reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that SVP, Commercial & Medical Affairs Rhonda Farnum received a grant of 18,750 Ordinary Shares of the company on April 1, 2026. The shares were granted at a stated price of $0.00 per share as compensation rather than a market purchase.
Following this award, Farnum directly holds a total of 251,449 Ordinary Shares of Theravance Biopharma, Inc., reflecting an increase in her equity-based compensation stake in the company.
Theravance Biopharma, Inc. announced a settlement of patent litigation over its YUPELRI® (revefenacin) inhalation solution. Theravance and its partner Mylan granted Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. starting on the Licensed Launch Date of April 23, 2039, subject to customary exceptions.
The agreement resolves all pending Hatch-Waxman patent disputes related to YUPELRI. The settlement will be reviewed by the U.S. Department of Justice and the Federal Trade Commission, as required for patent settlements involving branded and generic drug makers.
Weiss Asset Management and related entities filed Amendment No. 3 to their Schedule 13D on Theravance Biopharma, Inc. The filing reports beneficial ownership of 7,457,060 ordinary shares, representing 14.5% of Theravance’s outstanding shares, based on 51,492,924 shares outstanding as of February 28, 2026.
The filing notes that 4,628,074 shares, or 9.0% of the company, are held by BIP, and 2,828,986 shares, or 5.5%, are held by BGO. Weiss Asset Management LP serves as investment manager to both funds, and Andrew M. Weiss, through WAM GP LLC, has power to vote and dispose of these shares. The reporting persons state they have not effected any transactions in Theravance shares during the past 60 days.
Theravance Biopharma reports a pivotal shift in its business following mixed 2025 developments. YUPELRI® net sales rose 12% to $266.6 million, triggering a $25.0 million milestone from Viatris and reaching record annual sales and brand profitability.
The company sold its remaining TRELEGY® royalty interest to GSK for $225.0 million and received a $50.0 million TRELEGY milestone in 2026, while up to $100.0 million in additional TRELEGY milestones remain available. However, Phase 3 ampreloxetine (CYPRESS) failed its primary endpoint, leading to wind-down of that program.
In response, Theravance is implementing a restructuring that will wind down R&D, significantly reduce G&A, and is expected to cut operating expenses by about 60% versus 2025, delivering roughly $70 million in annualized savings from Q3 2026. A Strategic Review Committee is urgently evaluating alternatives, including a potential sale of the company, to maximize shareholder value.